Related Experiment Video
Updated: Oct 4, 2025
08:32
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
10.5K
Infliximab-induced hypoglycemia, a rare but relevant side effect
Lucía Zabalza1, Joaquín de Carlos2, Iranzu Ezcurra1
1Aparato Digestivo, Hospital García Orcoyen, España.
Revista Espanola De Enfermedades Digestivas
|February 4, 2022
Summary
Tumor necrosis factor (TNF) inhibitors have transformed immune-mediated disease treatment, particularly in inflammatory bowel disease (IBD). These therapies represent a significant advancement in managing IBD effectively.
Area of Science:
- Immunology
- Gastroenterology
- Pharmacology
Background:
- Tumor necrosis factor (TNF) inhibitors are crucial in treating immune-mediated diseases.
- Their application has revolutionized inflammatory bowel disease (IBD) management.
Discussion:
- TNF inhibitors offer a targeted approach to modulating immune responses in IBD.
- This class of drugs has improved patient outcomes and quality of life.
Key Insights:
- TNF inhibitors represent a paradigm shift in IBD therapy.
- Effective management of immune-mediated conditions relies on advanced biologic agents.
Outlook:
- Continued research into TNF inhibitors may yield further therapeutic innovations.
- Personalized medicine approaches will likely refine the use of TNF inhibitors in IBD.
Related Concept Videos
01:15Hypoglycemia and Glucagon
366
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
366
01:16Insulin: Dosing Regimen and Adverse Effects
294
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
294
01:23Dipeptidyl Peptidase 4 Inhibitors
279
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
279
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
305
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
305
01:06Oral Hypoglycemic Agents: Glinides
290
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
290
01:24Glucagon-like Receptor Agonists
461
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
461